Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Antibody-drug conjugate Stories

2014-04-04 23:36:36

Active research in breast cancer is producing novel targeted drugs at a rapid pace. Thousand Oaks, California (PRWEB) April 03, 2014 As the Cancer society continues research for breast cancer, several options have emerged. Of these options three drugs have been approved by the FDA for usage as treatment and no one is more excited than Dr. Mai Brooks. Perjeta (pertuzumab) In September 2013, the FDA approved Perjeta for use in combination with Herceptin (trastuzumab) and docetaxel for the...

2014-04-03 12:28:49

TUCSON, Ariz., April 3, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into an agreement with Genmab A/S, Copenhagen, Denmark for the development of companion diagnostic tools for Genmab's HuMax-TF®-ADC antibody drug conjugate (ADC) program. As part of the agreement, Ventana will provide its expertise and services towards the development of an immunohistochemistry (IHC) companion diagnostic test for the...

2014-04-03 08:21:56

DUBLIN, Apr. 03, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/zvzsf4/antibodydrug ) has announced the addition of the "Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis" report to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) The report entitled 'Antibody-Drug Conjugates 2014 - A Business, Technology & Pipeline Analysis' is based on the evaluation of more than 90 companies. The report...

2014-03-24 23:03:12

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that based on compelling data generated by the SMARTag™ ADC platform, it has increased its minority investment in Redwood Bioscience. The proprietary SMARTag precision protein-chemical engineering platform and novel toxin-linker technologies developed by Redwood enable the generation of homogeneous...

2014-03-10 23:24:25

Targeted drug aims to address high recurrence and lower survival in people with B-cell cancers. Raleigh, NC (PRWEB) March 10, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on new published research on an experimental Non-Hodgkin’s Lymphoma drug that appears to boost the power of existing medications. SNS01-T is a mixture of nanoparticles designed to interfere with the inner workings of malignant B-cells in patients with Non-Hodgkin’s Lymphoma and other B-cell cancers. A new...

2014-02-25 20:22:13

PASADENA, Calif., Feb. 25, 2014 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-drug conjugates using its proprietary monoclonal antibody (mAb) technology platform, today announced the issuance of its first patent, U.S. Patent No. 8,658,774, entitled "Novel Meditopes and Related Meditope-Monoclonal Antibody Delivery Systems, Synthesis and Therapeutic Uses Thereof." "We view the issuance of this patent, about two years from initial filing,...

2014-01-29 16:28:33

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/ztm9m5/antibodydrug) has announced the addition of the "Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis" [http://www.researchandmarkets.com/research/ztm9m5/antibodydrug ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The report entitled 'Antibody-Drug Conjugates 2014 - A Business,...

2014-01-15 08:29:14

OXFORD, England and SAN JOSE, California, January 15, 2014 /PRNewswire/ -- Oxford BioTherapeutics, an international biotechnology company developing antibody-drug conjugates for cancer, today announced the appointment of Thomas C Reynolds MD, PhD to its Board of Directors. Dr Reynolds has over 20 years' development experience gained in the biotechnology industry, most recently as Chief Medical Officer at Seattle Genetics. "I am delighted to welcome Tom at this...

2013-12-19 20:21:42

Transaction Provides Sorrento with Comprehensive Antibody Drug Conjugate Technology Platform SAN DIEGO, Dec. 19, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates (ADCs) with site-specific toxin conjugation and consistent drug-antibody ratios. With the...

2013-08-15 08:29:21

SAN DIEGO, Aug. 15, 2013 /PRNewswire/ -- We have come a long way in the use of electricity. In ancient Greece, Thales of Miletus discovered he could produce electrical sparks by rubbing amber with a cloth. In 1746, Pieter van Musschenbroek invented the Leyden jar to store static electricity. Two years after that, William Watson proposed the ideas of electric currents and electric circuits. Michael Faraday discovered that moving a magnet back and forth inside a wire coil could generate...